MoonLake Immunotherapeutics
MLTX
$16.47
-$0.03-0.18%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 4.60% | 40.66% | -0.10% | 46.41% | 58.13% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.58% | 47.47% | 31.54% | 65.69% | 98.50% |
| Operating Income | -1.58% | -47.47% | -31.54% | -65.69% | -98.50% |
| Income Before Tax | -10.29% | -70.98% | -35.41% | -95.93% | -126.73% |
| Income Tax Expenses | -5.26% | 306.54% | 504.88% | 25.00% | 20.25% |
| Earnings from Continuing Operations | -10.27% | -71.87% | -35.83% | -95.75% | -126.39% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -25.19% | 33.29% | 68.90% |
| Net Income | -11.93% | -74.51% | -36.89% | -97.03% | -127.55% |
| EBIT | -1.58% | -47.47% | -31.54% | -65.69% | -98.50% |
| EBITDA | -1.35% | -46.86% | -30.99% | -65.31% | -98.29% |
| EPS Basic | 4.17% | -54.82% | -27.02% | -95.54% | -126.06% |
| Normalized Basic EPS | 3.28% | -55.49% | -27.24% | -96.56% | -127.16% |
| EPS Diluted | 4.17% | -54.82% | -27.02% | -95.54% | -126.06% |
| Normalized Diluted EPS | 3.28% | -55.49% | -27.24% | -96.56% | -127.16% |
| Average Basic Shares Outstanding | 16.80% | 12.71% | 7.77% | 0.75% | 0.65% |
| Average Diluted Shares Outstanding | 16.80% | 12.71% | 7.77% | 0.75% | 0.65% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |